Xeloda 150mg and 500mg Film-coated Tablets (2011)
Active ingredients: Capecitabine
Product Name and Form
Xeloda 150 mg and 500 mg film-coated tablets.
Light peach film-coated tablet of biconvex, oblong shape with the marking ‘150’ on the one side and 'Xeloda' on the other side.
Peach film-coated tablet of biconvex, oblong shape with the marking ‘500’ on the one side and 'Xeloda' on the other side.
Qualitative and Quantitative Composition
150 mg or 500 mg capecitabine.
Excipient: 15.6 mg anhydrous lactose (150 mg tablet).
Excipient: 52 mg anhydrous lactose (500 mg tablet).
For a full list of excipients, see section 6.1.
Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU). There is evidence that the metabolism of 5-FU in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, thereby interfering with the synthesis of deoxyribonucleic acid (DNA). The incorporation of 5-FU also leads to inhibition of RNA and protein synthesis.
Titanium dioxide (E171)
Yellow and red iron oxide (E172)
Pack sizes and Marketing
Nature: PVC/PVDC blisters
150 mg: 60 film-coated tablets (6 blisters of 10 tablets)
500 mg: 120 film-coated tablets (12 blisters of 10 tablets)
Roche Registration Limited
6 Falcon Way
Welwyn Garden City
Date of first authorisation: 02 February 2001
Date of first renewal: 02 February 2006
EU/1/00/163/001 – 150 mg film-coated tablets
EU/1/00/163/002 – 500 mg film-coated tablets